| Objective: To study the condition and influencing factors of schizophrenia patientswith bone mass density(BMD) reduction. And then to provide scientific basis for theearly screening and targeted intervention of schizophrenia patients with osteoporosis. Inorder to improve the safety of clinical treatment.Methods: The research object is schizophrenia patients, hospitalized in theSeventh People’s Hospital of Dalian during the period of Oct.2013to Jan.2014, a totalof480people. Guiding the patients fill out a questionnaire, including general condition,diet, living habits, medication history, medical history, Positive and Negative SymptomScale (PANSS) score which collected through history-taking and search history data,BMD which is measured by dual energy X-ray absorptiometry. According to the resultsof BMD, patients are divided into normal BMD group, low BMD group andosteoporosis group. We define osteopenia group as low BMD group and osteoporosisgroup. The effects includes gender (male group, female group), age (<45group,≥45group), BMI (low BMI group, normal BMI group, high BMI group), dosage (monotherapy group, combination therapy group), medicine taking time(<10group,10-20group,20-30group), disease course (<15group,15-30group,≥30group). Package wereanalyzed statistically using SPSS17.0software. Firstly, single factor analysis, and then,multi factor Logistic regression analysis.Results:1.Osteopenia status of schizophrenia patients are as follows: TheOsteopenia and osteoporosis incidence is25%,25%. Among them7.5%,28.6%occurin men,42.2%,21.4%occur in women. The rank sum test results: the BMD femaleslower than males (P=0.00);≥45group is lower than those aged <45(P=0.00). 2.The results of single factor analysis as folows: BMD in male patients wassignificantly lower than the female (P=0.000).≥45years old group was higher thanthat in <45group (P=0.000), women and the elderly are risk factors for BMD. Malepatients, with BMI value increasing, the incidence rate of bone reduce decreaseslinearly (P=0.000), women have no linear trend (P=0.969). BMI value low is a riskfactor for decreased BMD. The BMI value increase will effect on BMD in malepatients than in female. Combination drug group’s BMD is lower than single druggroup (male P=0.000, female P=0.003). With the extension of medication time, theincidence rate of bone mass reducing growth trend linear (male P=0.000, femaleP=0.000), medication time is a risk factor for decreased BMD. With the extension ofschizophrenia duration, the incidence rate of bone mass reducing growth trend linear(male P=0.000, female P=0.000), schizophrenia duration is a risk factor for decreasedBMD. Osteopenia group’s positive, negative, general psychopathology, lack ofreaction, thought disorder, activation is higher than normal BMD group (P<0.01) inmale. Osteopenia group’s positive, negative, general psychopathology, lack of reaction,thought disorder, activation is higher than normal BMD group (P<0.01) in female.Composite score less than normal bone mass group (P=0.000).3.Multivariate Logistic regression analysis showed: in male patients medication,medication time, composite scale is the main influencing factors for BMD(P<0.05).Combined use of drugs, medication time are the main risk factors. In female patientsmedication, medication time, composite scale, years are the main influencing factors forBMD(P<0.05). Combined use of drugs, medication time, years are the main risk factors.Composite scores is the main protection factors.Conclusion:1.Drug combination, medicine time is the main influence factors forBMD in schizophrenia patients. We should try to single drug therapy to avoidcombination. They should regularly check BMD.2.Elderly female patients with schizophrenia is at high risk of BMD decrease, evenosteoporosis. So, during hospitalization they should be periodically tested BMD.3.For the body frail patients, we should pay attention to the diet, appropriateincrease of body weight in the normal range. |
PDF Full Text Request